Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Eli Lilly reports strong Q2 2025 growth, driven by Mounjaro & Zepbound. Highlights include increased guidance, pipeline updates, and key clinical milestones.

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

Discover how weight loss medications and smart nutrition can silence cravings in Food Noise by Dr. Jack Mosley.

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

US stocks trimmed losses on Thursday, finishing mixed after President Trump's sweeping tariffs hit dozens of US trade ...

Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a Sell.